Literature DB >> 21206981

Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application.

Lukasz Zapala1, Nadzieja Drela, Jacek Bil, Dominika Nowis, Grzegorz W Basak, Witold Lasek.   

Abstract

Dendritic cells (DCs) are specialized antigen-presenting cells that are present in peripheral tissues in a resting (immature) state. Their activation is a critical step in the initiation of the primary immune response. In the present study, we optimized in vitro conditions for maturation of commercially available immortalized mouse dendritic precursor JAWSII cells. These cells express surface markers and have properties that are typical of immature DCs and macrophages (e.g. MHC class I and II markers, CD80 molecules, high endocytic capacity), as well as TLR1, TLR3, TLR4, TLR6, and TLR7 receptors. When stimulated with poly I:C (and also LPS) JAWSII cells produced large amounts of IL-6, TNF-α and MCP-1. Incubation of JAWSII cells with IFN-γ markedly increased expression of MHC class I molecules and, more importantly, combination of this cytokine with poly I:C significantly increased expression of CD40 surface protein and CD11c, the most characteristic marker of mouse DCs. The combination of both agents also inhibited the endocytic abilities of JAWSII cells. In in vivo migration studies, exposure of JAWSII cells to poly I:C and IFN-γ led to increased accumulation of these cells in regional lymph nodes. Functional in vivo studies showed that tumor cell lysate-pulsed and subsequently poly I:C/IFN-γ-stimulated JAWSII cells promoted development of specific T cells in lymph nodes. Our studies show that the combination of optimal endogenous and exogenous ligands may induce phenotypic and functional maturation of JAWSII cells necessary for the accomplishment of their antigen-presenting function in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21206981     DOI: 10.3892/or.2010.1128

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Modifying Dendritic Cell Activation with Plasmonic Nano Vectors.

Authors:  Kieng Bao Vang; Ingrid Safina; Emilie Darrigues; Dmitry Nedosekin; Zeid A Nima; Waqar Majeed; Fumiya Watanabe; Ganesh Kannarpady; Rajshekhar A Kore; Daniel Casciano; Vladimir P Zharov; Robert J Griffin; Ruud P M Dings; Alexandru S Biris
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

2.  Dendritic cell biocompatibility of ether-based urethane films.

Authors:  Ingrid Safina; Karrer M Alghazali; Luke Childress; Christopher Griffin; Ahmed Hashoosh; Ganesh Kannarpady; Fumiya Watanabe; Shawn E Bourdo; Ruud P M Dings; Alexandru S Biris; Kieng Bao Vang
Journal:  J Appl Toxicol       Date:  2021-01-08       Impact factor: 3.446

3.  Quantification of cellular associated graphene and induced surface receptor responses.

Authors:  Zeid A Nima; Kieng Bao Vang; Dmitry Nedosekin; Ganesh Kannarpady; Viney Saini; Shawn E Bourdo; Waqar Majeed; Fumiya Watanabe; Emilie Darrigues; Karrer M Alghazali; Raad A Alawajji; Dayton Petibone; Syed Ali; Alexandru R Biris; Daniel Casciano; Anindya Ghosh; Gregory Salamo; Vladimir Zharov; Alexandru S Biris
Journal:  Nanoscale       Date:  2019-01-17       Impact factor: 8.307

4.  Evaluation of the Protective Efficacy of Poly I:C as an Adjuvant for H9N2 Subtype Avian Influenza Inactivated Vaccine and Its Mechanism of Action in Ducks.

Authors:  Aiguo Zhang; Hanzhang Lai; Jiahua Xu; Wenke Huang; Yufu Liu; Dawei Zhao; Ruiai Chen
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

5.  Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor.

Authors:  Piotr Humeniuk; Sabine Geiselhart; Claire Battin; Tonya Webb; Peter Steinberger; Wolfgang Paster; Karin Hoffmann-Sommergruber
Journal:  Sci Rep       Date:  2019-05-15       Impact factor: 4.379

6.  Evaluation of immunomodulatory effects of Boswellia sacra essential oil on T-cells and dendritic cells.

Authors:  Alia M Aldahlawi; Amani T Alzahrani; Mohamed F Elshal
Journal:  BMC Complement Med Ther       Date:  2020-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.